News

Fleet Bioprocessing will be attending the CADDA Annual Conference 2026 in Manchester on 15 September, with Alastair Dent representing the team.

Rapid lateral flow tests for plant health can support earlier decisions across growing sites, storage facilities, processing plants and inspection points. This article explains how sampling, extraction, assay format, environmental performance, reader-based interpretation and manufacturing transfer affect the reliability of rapid agricultural testing.

Fleet Bioprocessing provides flexible, end-to-end contract lateral flow assay development, supporting projects from critical reagent screening and proof of concept through optimisation, performance verification and transfer to manufacture.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

Fleet Bioprocessing is attending Med-Tech Expo 2026 at the NEC Birmingham on Wednesday 3rd June. We look forward to meeting researchers and industry partners working in diagnostics, assay technologies and healthcare innovation.

Just as careful antibody selection is critical for Lateral Flow Assay (LFA) performance, the choice of detector label and its conjugation strategy directly influences assay sensitivity, specificity, reproducibility and scalability. Detector labels convert binding events into measurable signals and the way these labels are prepared and evaluated has a profound impact on how reliably an assay performs. Gold nanoparticles have become the most widely used detector because of thei